STOCK TITAN

Acadia Pharmaceuticals Inc. - ACAD STOCK NEWS

Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Established with a commitment to scientific excellence and leadership in CNS research, Acadia's proprietary drug discovery platform has enabled the creation of a robust portfolio targeting conditions such as Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and schizophrenia.

Acadia's pivotal achievements include the development and commercialization of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, the first and only FDA-approved drug for the treatment of Rett syndrome. The company's clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

Situated in San Diego, one of the largest biotechnology hubs in the United States, Acadia benefits from proximity to over 400 companies and renowned research institutions like the Salk Institute for Biological Studies. This strategic location supports Acadia's mission to bring groundbreaking therapies to patients in need.

Financially, Acadia has shown significant growth, with total revenues reaching $205.8 million for the first quarter of 2024, reflecting a 74% year-over-year increase, largely due to the strong market performance of NUPLAZID and the addition of DAYBUE. The company continues to invest in its pipeline and commercial operations, maintaining a solid cash position with $470.5 million in cash, cash equivalents, and investment securities as of March 31, 2024.

Recent highlights include participation in major healthcare conferences, strategic appointments to enhance leadership in research and development, and ongoing efforts to expand the reach of DAYBUE beyond the U.S. market. Acadia’s unwavering dedication to advancing neuroscience and improving patient outcomes underscores its long-term growth potential and commitment to innovation in the biopharmaceutical landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences
-
Rhea-AI Summary

Acadia Pharmaceuticals will announce its first quarter financial results on May 8, 2023, after market close. A conference call and webcast will occur on the same day at 4:30 p.m. Eastern Time for discussing these results and company operations. The call will be available on Acadia's website and archived until June 7, 2023. Acadia is recognized for its innovative therapies in neuroscience, particularly for conditions like Parkinson’s disease psychosis and Rett syndrome. The company continues to focus on developing solutions for negative symptoms of schizophrenia and Alzheimer’s-related issues. Investors should note that forward-looking statements regarding future events may contain risks and uncertainties that could affect actual results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
-
Rhea-AI Summary

Acadia Pharmaceuticals (NASDAQ: ACAD) announced the presentation of four posters at the American Academy of Neurology (AAN) annual meeting from April 22 to 27, 2023, in Boston, Mass. The posters include a secondary analysis of communication-related endpoints from the Phase 3 LAVENDER™ study and an interim analysis of the DAFFODIL™ study. Notable presentations involve real-world physician surveys and an analysis of healthcare resource utilization in Rett syndrome patients. The poster P13 highlights the benefits of Trofinetide compared to placebo in communication abilities among individuals with Rett syndrome, thus showcasing the drug's potential. Rett syndrome is a rare neurological disorder affecting approximately 6,000 to 9,000 patients in the U.S., with Trofinetide being a key treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences clinical trial
Rhea-AI Summary

Acadia Pharmaceuticals has launched DAYBUE (trofinetide), the first FDA-approved therapy for Rett syndrome, a neurodevelopmental disorder affecting 6,000 to 9,000 patients in the U.S. The drug is available for individuals aged two and older and was officially approved on March 10, 2023. The company emphasizes its commitment to patient support, expanding the Acadia Connect program to enable access to this therapy through financial assistance and prescription support. Notable endorsements from healthcare professionals highlight DAYBUE's potential to improve symptoms and enhance patients' quality of life.

Common side effects include diarrhea (experienced by 85% of patients) and weight loss (12% had losses exceeding 7%). Acadia continues to focus on treatments addressing unmet medical needs in the field of neuroscience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
none
-
Rhea-AI Summary

Acadia Pharmaceuticals (Nasdaq: ACAD) will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 p.m. Eastern Time. The conference will be held virtually, and a live webcast of the presentation can be accessed on the company’s website under the investors section. An archived recording will be available for about one month post-event.

Acadia Pharmaceuticals specializes in advancing neural breakthroughs, having developed the first therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for Rett syndrome. Its clinical efforts are aimed at addressing symptoms of several central nervous system disorders, including schizophrenia and Alzheimer’s disease psychosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences
-
Rhea-AI Summary

Acadia Pharmaceuticals has received FDA approval for DAYBUE (trofinetide), the first and only treatment for Rett syndrome affecting 6,000 to 9,000 patients in the U.S. The drug is expected to be available by the end of April 2023.

The approval is supported by the pivotal Phase 3 LAVENDER study, which demonstrated statistically significant improvements in Rett symptoms compared to placebo. Additionally, Acadia received a Rare Pediatric Disease Priority Review Voucher.

Acadia’s CEO stated the approval marks a crucial milestone for patients and families lacking treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
Rhea-AI Summary

Acadia Pharmaceuticals Inc. reported full-year 2022 net sales of $517.2 million, a 7% increase from 2021, driven by strong demand for NUPLAZID®. The fourth-quarter sales reached $136.5 million, up 4% year-over-year. The company anticipates a transformative 2023, with a PDUFA action date for trofinetide set for March 12, 2023. However, Acadia reported a net loss of $216 million for 2022, increasing from $167.9 million the previous year. For 2023, projected net sales for NUPLAZID are between $520 million to $550 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
-
Rhea-AI Summary

Acadia Pharmaceuticals (NASDAQ: ACAD) will announce its fourth quarter and full year 2022 financial results on February 27, 2023, after U.S. market close.

The company will host a conference call and webcast that same day at 4:30 p.m. Eastern Time to discuss these results and operational updates. Interested participants can register for the call via Acadia's website.

Acadia is focused on neuroscience breakthroughs, developing therapies for conditions like Parkinson's disease psychosis, schizophrenia, and Alzheimer's disease psychosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary

Acadia Pharmaceuticals announced the grant of inducement awards on February 10, 2023, to 19 new employees under its 2023 Inducement Plan. This includes non-qualified stock options for 310,065 shares and 97,251 restricted stock units (RSUs). The options have an exercise price of $18.97 and will vest over four years. Notably, Douglas J. Williamson, the new Executive VP of Research & Development, received options for 237,296 shares and RSUs for 50,655 shares. These awards are designed to incentivize new hires and comply with Nasdaq regulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
Rhea-AI Summary

Acadia Pharmaceuticals has appointed Dr. Doug Williamson as Executive Vice President, Head of Research and Development. Dr. Williamson, succeeding Dr. Srdjan Stankovic, brings over 20 years of neuroscience R&D experience, most recently serving as Chief Medical Officer at Avadel Pharmaceuticals. His leadership is expected to play a crucial role as Acadia prepares for the potential approval of trofinetide for Rett syndrome and advances its clinical programs. This strategic move aims to strengthen Acadia's position in the neuroscience market during a pivotal time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
management

FAQ

What is the current stock price of Acadia Pharmaceuticals (ACAD)?

The current stock price of Acadia Pharmaceuticals (ACAD) is $16.87 as of December 20, 2024.

What is the market cap of Acadia Pharmaceuticals (ACAD)?

The market cap of Acadia Pharmaceuticals (ACAD) is approximately 2.8B.

What does Acadia Pharmaceuticals Inc. specialize in?

Acadia Pharmaceuticals Inc. specializes in developing and commercializing innovative medicines for central nervous system (CNS) disorders.

Where is Acadia Pharmaceuticals headquartered?

Acadia Pharmaceuticals is headquartered in San Diego, California.

What are some of Acadia's key products?

Key products include NUPLAZID, for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, for the treatment of Rett syndrome.

What recent financial performance did Acadia report?

For the first quarter of 2024, Acadia reported total revenues of $205.8 million, marking a 74% increase year over year.

What are Acadia's current research focuses?

Acadia's research focuses include the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

What recent achievements has Acadia Pharmaceuticals announced?

Recent achievements include strategic leadership appointments, participation in major healthcare conferences, and advancements in their clinical-stage development efforts.

How does Acadia support the Rett syndrome community?

Acadia supports the Rett syndrome community through initiatives like the Rett Sibling Scholarship program and creating awareness with projects like Magnolia’s Guide to Adventuring.

What is the significance of Acadia's location in San Diego?

San Diego is one of the largest biotechnology clusters in the U.S., providing Acadia access to a vibrant ecosystem of over 400 companies and prestigious research institutions.

How has Acadia's product portfolio grown recently?

Acadia's portfolio has grown with the addition of DAYBUE, enhancing their market presence and addressing unmet medical needs in CNS disorders.

What is Acadia’s approach to drug discovery?

Acadia’s proprietary drug discovery platform focuses on internal discoveries, innovative therapeutic approaches, and addressing large unmet needs in CNS disorders.

Acadia Pharmaceuticals Inc.

Nasdaq:ACAD

ACAD Rankings

ACAD Stock Data

2.80B
164.23M
0.55%
97.52%
6.16%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO